Literature DB >> 31471816

Kidney transplantation in ANCA-associated vasculitis.

Michael S Sagmeister1, Melissa Grigorescu2, Ulf Schönermarck3.   

Abstract

The kidney is commonly affected in patients with ANCA-associated vasculitis (AAV), causing end-stage renal disease (ESRD) in 20-40% of cases. Kidney transplantation is the treatment of choice for eligible patients with ESRD due to AAV. This review provides a summary of patient and graft outcome after kidney transplantation in AAV patients, the risk of relapse and the optimal time of transplantation. We also address the rare event of de novo ANCA-associated vasculitis after kidney transplantation and the treatment options.

Entities:  

Keywords:  ANCA vasculitis; De novo; Kidney transplantation; Relapse

Mesh:

Year:  2019        PMID: 31471816     DOI: 10.1007/s40620-019-00642-x

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  49 in total

1.  Risk of renal allograft loss from recurrent glomerulonephritis.

Authors:  Esther M Briganti; Graeme R Russ; John J McNeil; Robert C Atkins; Steven J Chadban
Journal:  N Engl J Med       Date:  2002-07-11       Impact factor: 91.245

2.  Two cases of ANCA-associated vasculitis in post-transplant kidney: relapse and de novo.

Authors:  Hidehiro Tabata; Kazuho Honda; Takahito Moriyama; Mitsuyo Itabashi; Sekiko Taneda; Takashi Takei; Kazunari Tanabe; Satoshi Teraoka; Yutaka Yamaguchi; Hideaki Oda; Kosaku Nitta
Journal:  Clin Transplant       Date:  2009-08       Impact factor: 2.863

Review 3.  End-stage renal disease in ANCA-associated vasculitis.

Authors:  Sergey Moiseev; Pavel Novikov; David Jayne; Nikolay Mukhin
Journal:  Nephrol Dial Transplant       Date:  2017-02-01       Impact factor: 5.992

4.  Renal transplantation in Wegener's granulomatosis.

Authors:  W H Schmitt; M Haubitz; N Mistry; R Brunkhorst; B Erbslöh-Möller; W L Gross
Journal:  Lancet       Date:  1993-10-02       Impact factor: 79.321

Review 5.  Recurrence of anti-neutrophil cytoplasmic antibody vasculitis in the kidney allograft.

Authors:  David Lau; Shaun Summers; Liv Amos; Ian Simpson; William Mulley
Journal:  Nephrology (Carlton)       Date:  2012-04       Impact factor: 2.506

Review 6.  ANCA-associated vasculitis with renal involvement.

Authors:  Valentina Binda; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-30       Impact factor: 3.902

7.  The clinical course of ANCA small-vessel vasculitis on chronic dialysis.

Authors:  Sofia Lionaki; Susan L Hogan; Caroline E Jennette; Yichun Hu; Julie B Hamra; J Charles Jennette; Ronald J Falk; Patrick H Nachman
Journal:  Kidney Int       Date:  2009-06-17       Impact factor: 10.612

8.  Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients.

Authors:  N Kamar; O Milioto; B Puissant-Lubrano; L Esposito; M C Pierre; A Ould Mohamed; L Lavayssière; O Cointault; D Ribes; I Cardeau; M B Nogier; D Durand; M Abbal; A Blancher; L Rostaing
Journal:  Am J Transplant       Date:  2009-07-28       Impact factor: 8.086

9.  Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis.

Authors:  A Allen; C Pusey; G Gaskin
Journal:  J Am Soc Nephrol       Date:  1998-07       Impact factor: 10.121

Review 10.  Rituximab in renal transplantation.

Authors:  A Nicholas R Barnett; Vassilis G Hadjianastassiou; Nizam Mamode
Journal:  Transpl Int       Date:  2013-02-18       Impact factor: 3.782

View more
  2 in total

1.  Very Early Severe Posttransplant Recurrent Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis after Kidney Transplantation: Two Case Reports.

Authors:  Reda Laamech; Hamza Naciri-Bennani; Diane Giovannini; Johan Noble; Bénédicte Janbon; Paolo Malvezzi; Thomas Jouve; Lionel Rostaing
Journal:  Case Rep Nephrol       Date:  2022-03-03

Review 2.  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Kidney Transplantation.

Authors:  Valentina Binda; Evaldo Favi; Marta Calatroni; Gabriella Moroni
Journal:  Medicina (Kaunas)       Date:  2021-12-03       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.